Supplementation of Lys, Met, and Thr in milk replacers (MR) has been widely studied, but scarce information exists about potential roles of other amino acids (either essential or not). The effects on growth performance of supplementation of 4 different amino acid (AA) combinations in a MR (25.4% CP and 20.3% fat) based on skim milk powder and whey protein concentrate were evaluated in 76 dairy Holstein male calves (2.8 ± 0.14 d old): Control without additional AA supplementation; PG providing 0.3% Pro and 0.1% Gly, respectively; FY supplying 0.2% Phe and 0.2% Tyr, respectively; KMT containing 0.62% Lys, 0.22% Met, and 0.61% Thr, respectively. All calves received the same MR feeding program and were weaned at 56 d of study. Concentrate intake was limited to minimize interference of potential differences in solid feed intake among treatments. Animals were weighed weekly, intakes recorded daily, and blood samples obtained at 2, 5, and 7 wk of study to determine plasma AA concentrations. At 7 wk of study, carcass composition was evaluated using CT in 8 calves per treatment. Data were analyzed with a mixed-effects model with repeated measures. There were no differences in growth rate among treatments (0.84 ± 0.022 kg/d), but fat carcass content was greater in Control than in FY calves, and similar among the other MR supplementation (5.95 vs 5.23 vs 5.29 vs 5.36 ± 0.181% in Control, FY, PG, and KMT, respectively). Plasma concentration (both in absolute values or relative to total AA concentration) of all AA that were supplemented increased (P < 0.01) with the exception of Gly that maintain similar values in all 4 treatments. However, only KMT resulted in a reduction (P < 0.05) of Asn/Ser, His, Pro, Val, Leu, and Ile relative proportions in plasma, suggesting an improved use of these AA when KMT was supplemented. Although no differences in growth performance were observed when supplementing the AA combinations tested herein, some metabolic changes could be envisaged considering carcass fat deposition when supplementing FY and changes in plasma AA profile changes when supplementing KMT.